

PATENT
ATTORNEY DOCKET NO.: GENE1120-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Nolan and Filshie	Art Unit:	1636
Application No.:	09/342,024	Examiner:	G. Leffers, Jr.
Filed:	June 28, 1999		
Title:	HIGH EFFICIENCY TRANSFECTION BASED ON LOW ELECTRIC FIELD STRENGTH, LONG PULSE LENGTH		

Commissioner for Patents
Washington, D.C. 20231

DECLARATION OF DR. DIETMAR P. RABUSSAY
UNDER 37 C.F.R. §1.132

Sir:

I, Dr. Dietmar P. Rabussay, do hereby declare and state that:

1. I presently hold the position of Vice President of Research and Development at Genetronics, Inc., having a place of business at 11199-A Sorrento Valley Road, San Diego, California 92121-1334

2. I hold a degree of M.Sc. (Diplomingenieur) in Chemistry granted by the Technical University of Graz, Austria in 1967 and a degree of Ph.D. (Dr. rer. Nat.) from the University of Munich, Germany, granted in 1971.

3. I have been involved in the electroporation field for over twenty years and am an author on over fifty publications, of which sixteen concern electroporation, a list of which is

Applicants: Nolan, et al.
Application No.: 09/342,024
Filed: June 28, 1999
Page 2

attached hereto. I am also a named inventor on no less than five issued patents on electroporation technology.

4. I am familiar with the content of the above-identified application, including the methods for introducing nucleic acid into a cell of a mammalian subject *in vivo*. In addition, I have studied the Examiner's reasons in support of the rejection of claims 1-2, 4-11, 19-20 and new claims 30, 31, 34, 36, 37 and 39 of the above-identified application under 35 U.S.C. § 102(e) as allegedly being anticipated by U. S. Patent No. 5,944,710 to Dev et al. (hereinafter "the Dev patent").

5. I am also familiar with the Dev patent, particularly with disclosure contained therein pertaining to ranges of electric field strength and pulse length suitable for *in vivo* delivery of nucleic acid into a cell, especially cells of a mammalian subject. I disagree with the Examiner's assertion that the Dev patent discloses selecting and utilizing a *combination* of electric field strength and pulse length as claimed by the Applicants of the above-described application for *in vivo* delivery of nucleic acid into a mammalian cell. In fact, the Dev patent discloses (Dev col. 11, first full paragraph) that the preferred pulse duration range is 500 microseconds to 10 milliseconds. This is clearly below the claimed range of about 10 milliseconds to about 100 milliseconds. Thus, the Dev patent contains an express teaching of a preferred range for pulse duration that lies substantially outside the claimed range, showing that the focus of the Dev patent, and the skilled artisan's attention is directed to other than the claimed invention.

Applicants: Nolan, et al.
Application No.: 09/342,024
Filed: June 28, 1999
Page 3

Additionally, I disagree with the Examiner's assertion that disclosure in the Dev patent of electroporation-enhanced delivery of nucleic acids intravascularly using electric fields in a broad range of at least 100-2,000V/cm (or higher), anticipates the claimed field strength range because the Dev patent also teaches that "mammalian cells typically require between 0.5 and 5.0 kV/cm" [or 500-5000 V/cm] before electroporation will occur (Dev, Col 10, lines 34-36). Thus, the Dev patent specifically discloses a field strength range appropriate for electroporation of mammalian cells that excludes most of the voltage range recited in claims 1 and 39 of the above-identified application.

Of even greater importance, there is no disclosure in the Dev patent that the *combination* of field strength of about 300-600 volts per centimeter and pulse duration of 10-100 milliseconds is to be selected and used for the case wherein nucleic acid is delivered to mammalian cells. The Dev patent discloses that the pulse length to be used for electroporation of cells can be between 100 microseconds to 100 milliseconds, preferably 500 microseconds to 10 milliseconds. Yet only a pulse length of 0.76 milliseconds was used in the Example.

GENETRONICS INC

PATENT
ATTORNEY DOCKET NO.: GENE1120-1

Applicants: Nolan, et al.
Application No.: 09/342,024
Filed: June 28, 1999
Page 4

Thus, it is my observation and opinion that the Dev patent not only fails to disclose selection of the particular combination of field strength and pulse duration for electroporation enhanced *in vivo* delivery of nucleic acids to mammalian cells that is the subject matter of claims 1 and 39 of the above-described application, but in fact actually leads away from using such conditions. As a scientist who has been intimately involved in the electroporation industry for many years, it is clear that one of skill in the electroporation art would understand that Dev did not disclose each and every element of the presently claimed invention and further has not lead any artisan in the electroporation arts to be lead to use such conditions. Rather, use of the conditions claimed in the present application are new and provide an unexpected and surprising result in this art.

4. I further declare that all statements made herein of knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine, or imprisonment, or both under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: December 19, 2002


Dr. Dietmar P. Rabussay

PUBLICATION LISTING

DIETMAR RABUSSAY, PH.D.

Publications in Journals and Symposium Volumes

1. Illaszewicz, A., Müller, K., Rabussay, D., and Spitzzy, H. Redoxmethoden mit neutronenaktiviertem Silbermetall (^{110m}Ag) als Radioreagenz. *J. Radioanal. Chem.* 1, 39-49, 1968.
2. Rabussay, D., Herrlich, P., Schweiger, M. and Zillig, W. More evidence for bacteria-like protein synthesizing apparatus in chloroplasts and mitochondria. *FEBS-Letters* 4, 55-56, 1969.
3. Rabussay, D. and Zillig, W. A rifampicin resistant RNA polymerase from *E. coli* altered in the β -subunit. *FEBS-Letters* 5, 104-106, 1969.
4. Zillig, W., Fuchs, E., Palm, P., Rabussay, D. and Zechel, K. On the different subunits of DNA-dependent RNA polymerase from *E. coli* and their role in the complete function of the enzyme. In: *RNA-Polymerase and Transcription*. L. Silvestri (Editor), North Holland Publishing Company, Amsterdam, London, 151-157, 1970.
5. Rabussay, D., Zillig, W. and Herrlich, P. Characterization of the *Bacillus stearothermophilus* phage $\Phi\mu$ -4 and its DNA. *Virology* 41, 91-100, 1970.
6. Zillig, W., Palm, P., Sethi, V. S. and Rabussay, D. The role of different subunits of DNA-dependent RNA polymerase in the complex function of the enzyme. In: *Annals of the New York Academy of Sciences* 171, 910-914, 1970.
7. Zillig, W., Zechel, K., Rabussay, D., Schachner, M., Sethi, V. S., Palm, P., Heil, A. and Seifert, W. On the role of different subunits of DNA-dependent RNA polymerase from *E. coli* in the transcription process. *Cold Spring Harbor Symp. Quant. Biol.* 35, 47-58, 1970.
8. Seifert, W., Rabussay, D. and Zillig, W. On the chemical nature of alteration and modification of DNA-dependent RNA polymerase of *E. coli* after T4 infection. *FEBS-Letters* 16, 175-179, 1971.
9. Schäfer, R., Mailhammer, R., Rabussay, D., Seifert, W., Sethi, V. S. and Zillig, W. A micro-procedure for the preparation of highly purified ^{14}C - ^{32}P -, and ^{35}S -labeled transcriptases from *E. coli*. *Hoppe-Seyler's Z. Physiol. Chem.* 352, 1398-1400, 1971.
10. Pilz, I., Kratky, O. and Rabussay, D. Studies on the conformation of DNA-dependent RNA polymerase in solution by small-angle X-ray measurements. *European Journal of Biochemistry* 28, 205-220, 1972.
11. Rabussay, D., Mailhammer, R. and Zillig, W. Regulation of transcription by T4-phage induced chemical alteration and modification of transcriptase (EC 2.7.7.6). In: *Metabolic Interconversion of Enzymes*, O. Wieland, E. Helmreich, H. Holzer (Editors), Springer-Verlag, Berlin-Heidelberg-New York, 213-227, 1972.
12. Wu, R., Geiduschek, E. P., Rabussay, D. and Cascino, A. Regulation of transcription in bacteriophage T4-infected *E. coli* - a brief review and some recent results. In: *Virus Research - Proceeding of the Second ICN-UCLA Symposium on Molecular Biology*, C. F. Fox and W. S. Robinson (Editors), Academic Press, New York and London, 181-204, 1973.

13. Duffy, J. J., Petrussek, R. L., Rabussay, D. and Geiduschek, E. P. Hydroxymethyluracil bacteriophages of *B. subtilis*: Involvement of RNA polymerase in the regulation of bacteriophage SPO1 development. *Microbiology* 1976, D. Schlessinger (Editor), American Society for Microbiology, Washington, D.C., 280-289, 1976.
14. Rabussay, D. and Geiduschek, E. P. Phage T4-modified RNA polymerase transcribes T4 late genes *in vitro*. *Proc. Natl. Acad. Sci. U.S.A.* 74, 5305-5309, 1977.
15. Rabussay, D. and Geiduschek, E. P. Construction and properties of a cell-free system for phage T4 late RNA synthesis. *J. Biol. Chem.* 254, 339-349, 1979.
16. Rabussay, D. and Geiduschek, E. P. Relation between bacteriophage T4 DNA replication and late transcription *in vitro* and *in vivo*. *Virology* 99, 286-301, 1979.
17. Kassavetis, G. A., Elliott, T., Rabussay, D. and Geiduschek, E. P. Initiation of transcription at phage T4 late promoters with purified RNA polymerase. *Cell* 33, 887-897, 1983.
18. Xia, Y., Burbank, L., Uher, L., Rabussay, D. and Van Etten, J. L. Restriction endonuclease activity induced by PBCV-1 virus infection of a *Chlorella* - like green alga. *Molecular and Cellular Biology*, 6, 1430-1439, 1986.
19. Xia, Y., Burbank, D. E., Uher, L., Rabussay, D. and Van Etten, J. L. IL-3A virus infection of a *Chlorella* - like green alga induces a DNA restriction endonuclease with novel sequence specificity. *Nucleic Acids Research* 14, 6017-6030, 1987.
20. Rabussay, D., Uher, L., Bates G. and Piastuch, W. Electroporation of mammalian and plant cells. *FOCUS* 9(3), 1-5, 1987.
21. Bates, G. W., Piastuch, W., Riggs, C. D., and Rabussay, D. Electroporation for DNA delivery to plant protoplasts. *Plant Cell, Tissue and Organ Culture* 12, 213-218, 1988.
22. Rabussay, D. and Cornelia, R. E. The barrier integrity monitor. In: *Hospital Management International* (Leslie Paine, Editor), Sterling Publications, Ltd., London and Hong Kong, 203-205, 1993.
23. Rabussay, D. Infection control and latex glove failure. *Medical Electronics*, 165, 46-48, 1997.
24. Widera, G., Austin, M., Rabussay, D., Goldbeck, C., Barnett, S. W., Chen, M., Leung, L., Otten, G. R., Thudium, K., Selby, M. J., and Ulmer, J. B. Increased DNA vaccine delivery and immunogenicity by electroporation *in vivo*. *The Journal of Immunology*, 164, 4635-4640, 2000.
25. Dev, N. B., Hofmann, G. A., Dev, S. B. and Rabussay, D. P. Intravascular electroporation markedly attenuates neointima formation after balloon injury of the carotid artery in the rat. *Journal of Interventional Cardiology*, 13(5), 331-338, 2000.
26. Wallace, M. S., Ridgeway, B., Jun, E., Schulteis, G., Rabussay, D. and Zhang, L. Topical delivery of lidocaine in healthy volunteers by electroporation, electroincorporation, or iontophoresis: An evaluation of skin anesthesia. *Regional Anesthesia and Pain Medicine*, 26(3), 229-238, 2001.
27. Nanda, G. S., Blecher, S., Dev, S. B. and Rabussay, D. P. Electroporation therapy of head and neck tumors. In: *Oral Oncology*, Vol. VII, 318-322, A. K. Varma and J. L. N. Roodenburg (eds.), MacMillan India, Ltd., 2001.

28. Nanda, G. S. and Rabussay, D. P. Safety of head and neck tumor treatment by electroporation therapy: Effect on healthy tissue. In: Oral Oncology, Vol. VII, 326-331, A.K. Varma and J.L.N. Roodenburg (eds.), MacMillan India, Ltd., 2001.
29. Rabussay, D. P., Nanda, G. S., and Goldfarb, M. P. Enhancing the effectiveness of drug-based cancer therapy by electroporation (electropermeabilization). *Technology in Cancer Research & Treatment*, 1, 71-82, 2002.
30. Zhang, L. and Rabussay, D. P. Clinical evaluation of safety and tolerance of electrical sensation induced by non-invasive skin electroporation. *Bioelectrochemistry*, 56, 233-236, 2002.
31. Babiuk, S., Baca-Estrada, M. E., Foldvari, M., Storms, M., Rabussay, D., Widera, G. and Babiuk, L. A. Electroporation improves the efficacy of DNA vaccines in large animals. *Vaccine*, 20, 3399-3408, 2002.
32. Dev, S. B., Nanda, G. S., Bleecher, S., Rabussay, D. P., Moerland, T. S., Caban, J. B., Gibbs, S. J. and Locke, B. R. Magnetic resonance studies of laryngeal tumors implanted in nude mice: Effect of treatment with bleomycin and electroporation, *Magnetic Resonance Imaging*, 20, 389-394, 2002.
33. Zhang, L., Nolan, E., Kreitschitz, S. and Rabussay, D. P. Enhanced delivery of naked DNA to the skin by non-invasive in vivo electroporation. *Biochim. Biophys. Acta*, 1572, 1-9, 2002.
34. Krassowska, W., Nanda, G. S., Austin, M. B., Dev, S. B. and Rabussay, D. P. Viability of cancer cells exposed to pulsed electric fields: The role of pulse charge, *Ann. Biomed. Engineering*, (in press).
35. Rabussay D, Dev NB, Fewell J, Smith LC, Widera G, Zhang L. Enhancement of therapeutic and DNA delivery into cells by electroporation. *Journal of Physics D*, (in press).
36. Babiuk, S., Baca-Estrada, M. E., Foldvari, M., Baizer, L., Stout, R., Storms, M., Rabussay, D., Widera, G., and Babiuk, L. A. Improving efficacy of DNA vaccination to skin by non-invasive electroporation in pigs. *Vaccine*, (Submitted).

Review Articles

1. Rabussay, D. and Geiduschek, E. P. Regulation of gene action in the development of lytic bacteriophages. *In: Comprehensive Virology*, H. Fraenkel-Conrat and R. R. Wagner (Editors), Plenum Press, New York and London, 1-196, 1977.
2. Hartman, C. and Rabussay, D. *E. coli* DNA polymerase I: Enzymatic functions and their application in polymer formation, nick translation and DNA sequencing. *In: Gene Amplification and Analysis*, Vol. 2: Analysis of Nucleic Acid Structure by Enzymatic Methods, J. Chirikjian and T. Papas (Editors), 18-39, Elsevier/North Holland Biomedical Press, Amsterdam and New York, 1981.
3. Rabussay, D. Bacteriophage T4 infection mechanisms. *In: The Molecular Action of Toxins and Viruses*, P. Cohen and S. Van Heynigen (Editors), 219-331, Elsevier/North-Holland Biomedical Press, Amsterdam, New York and Oxford, 1982.
4. Rabussay, D. Changes of *Escherichia coli* RNA polymerase after bacteriophage T4 infection. *ASM (American Society for Microbiology) News* 48, 398-403, 1982.
5. Brody, E. Rabussay, D. and Hall, D. H. Regulation of the transcription of pre-replicative genes. *In: Bacteriophage T4*, C. Mathews, E. M. Kutter, G. Mosig and P. B. Berget (Editors), 174-183, American Society for Microbiology, Washington D.C., 1983.
6. Rabussay, D. Phage-evoked changes in RNA polymerase. *In: Bacteriophage T4*, C. Mathews, E. M. Kutter, G. Mosig and P. B. Berget (Editors), 167-173. American Society for Microbiology, Washington, D.C., 1983.
7. Bates, G. W., Rabussay, D. and Piastuch, W. Transient and stable expression of foreign DNA introduced into plant protoplasts by electroporation. *In: Methods in Molecular Biology*, Vol. 6, Plant Cell and Tissue Culture, JW. Pollard and J.M. Walker (Editors), 309-322, The Humana Press, 1990.
8. Korniewicz, D. M. and Rabussay, D. Surgical glove failures in clinical practice settings. *AORN Journal* 66, 660-673, 1997.
9. Rabussay, D. and Korniewicz, D. M. The risks and challenges of surgical glove failures. *AORN Journal* 66, 887-888, 1997.
10. Rabussay, D. and Korniewicz, D. M. Improving glove barrier effectiveness. *AORN Journal* 66, 1043-1063, 1997.
11. Rabussay, D. Improvement of glove barrier effectiveness by electronic monitoring. *Journal of Healthcare Safety, Compliance and Infection Control* 1, 63-77, 1997.
12. Rabussay, D. Frequently asked questions about Electroporation Therapy. *Medical Electronics* 170, 64-68, 1998.
13. Hofmann, G. A., Dev, S. B., Nanda, G. S. and Rabussay, D. Electroporation therapy of solid tumors. *Critical Reviews in Therapeutic Drug Carrier Systems*, 16(6), 523-569, 1999.
14. Dev, S. B., Rabussay, D., Widera, G. and Hofmann, G. A. Medical applications of Electroporation. *IEEE Transactions on Plasma Science*, 28(1), 206-223, 2000.
15. Rabussay, D. and Widera, G. Electroporation mediated drug and DNA delivery in oncology and gene therapy. *Drug Delivery Technology*, 2(3), 34-40, 2002.

Abstracts and Short Reviews

1. Herrlich, P., Schweiger, M., Rabussay, D. and Zillig, W. Two classes of protein synthesizing systems differing in mRNA-ribosome interaction. Classification of mitochondrial and chloroplast protein synthesis. *Abstract* of a paper presented at the 5th FEBS Meeting, Prague, 1968, Abstract No. 581.
2. Zillig, W., Palm, P., Sethi, V. S., Zechel, K. and Rabussay, D. Role of different subunits of DNA-dependent RNA polymerase in the complex function of the enzyme. *Abstract* of a paper presented at the 8th International Congress of Biochemistry, 1970, Abstract 176.
3. Zechel, K., Rabussay, D., and Zillig, W. Nachweis einer Substrat-unabhaengigen kooperativen Umwandlung des RNA-Enzym-Komplexes vor Beginn der RNA-Synthese. *Abstract* of a paper presented at the Wintertagung der Gesellschaft fuer Biologische Chemie in Wuerzburg, Hoppe-Seyler's Z. Physiol. Chem. 351:136, 1970.
4. Zillig, W., Heil, A., Palm, P., Zechel, K., Seifert, W. and Rabussay, D. Struktur, Funktion and Modifikation der DNA-abhängigen RNA-Polymerase aus *E. coli*. *Abstract* of a paper presented at the International Symposium Reinhardtsbrunn, 1971.
5. Rabussay, D., Mailhammer, R. and Zillig, W. T4-Phage induced changes of the host RNA polymerase. *Abstract* of a paper presented at the European Phage Meeting, Berlin, 1971.
6. Zillig, W., Rabussay, D. and Mailhammer, R. Regulation of transcription by chemical alternation and modification of transcriptase. *Abstract* of a paper presented at the 6, Konferenz der Gesellschaft Deutscher Naturforscher und Ärzte and Second International Symposium on "Metabolic Interconversion of Enzymes", Rottach-Egern, Abstract 21, 1971.
7. Zillig, W., Heil, A., Palm, P., Rabussay, D. and Mailhammer, R. Structure, function and regulation of DNA-dependent RNA polymerase from *E. coli*. In: *Reaction Mechanisms and Control Properties of Phosphotransferases*, edited by the Biochemische Gesellschaft der DDR, Akademie-Verlag, Berlin, 527-529, 1973.
8. Zillig, W., Palm, P., Heil, A., Schäfer, R., Zechel, K., Rabussay, D., Mailhammer, R. and Portmann, R. Structure and function of transcriptase and the regulation of transcription. *Abstract* of a paper presented at the Symposium on "Polymerization Reactions in Biological Systems", London, March 1972.
9. Rabussay, D. and Geiduschek, E. P. Transcription of T4 late RNA *in vitro*. *Abstract* of a paper presented at the fall meeting of the Society for Biological Chemistry and the Swiss and Austrian Biochemical Societies, Innsbruck, Austria. Hoppe-Seyler's Z. Physiol. Chem. 354:231, 1973.
10. Rabussay, D. and Geiduschek, E. P. RNA synthesis during the post-replicative period in phage T4-infected *E. coli*. *Abstract* of a paper presented at the 10th International Congress of Biochemistry, Hamburg, Germany, July 1976.
11. Rabussay, D. Regulation of post-replicative T4 RNA synthesis – an *in vitro* system. *Federation Proceedings* 35:1613, 1976.
12. Rabussay, D. and Geiduschek, E. P. Transcription of late, middle and early genes of bacteriophage T4 *in vitro*. *Abstract* of a paper presented at the Annual Meeting of the American Society for Microbiology, Las Vegas, Nevada 1978.

13. Rabussay, D. Bacteriophage T4 late gene transcription in an *in vitro* system. *Abstract* of a paper presented at the Fourth International Congress for Virology, The Hague, The Netherlands, 1978.
14. Rabussay, D. Late transcription of bacteriophage T4 requires certain functional replication proteins but not DNA synthesis. *Hoppe-Seyler's Z. Physiol. Chem.* 360, 347, 1979.
15. Rabussay, D. Regulation of gene expression during T4 development. *Abstract* of a paper presented at the 80th Annual Meeting of the American Society for Microbiology, Miami, Florida, May 1980.
16. Rabussay, D. Transcription of bacteriophage T4 late genes *in vitro*. *Abstract* of a paper presented at the EMBO workshop on Protein-DNA Interactions in Bacteriophages, Salamanca, Spain, July 1980.
17. Rabussay, D. The effect of RNA polymerase subunit σ on the transcription ratio of pre-replicative and post-replicative genes of bacteriophage T4. *Abstract* of paper presented at the 1981 West Coast Phage Meeting, Olympia, Washington, August 1981.
18. Kotewicz, M. L., Rabussay, D. and deKloet, S. R. The use of Lyticase in yeast transformation and isolation of nucleic acids. *Abstract* of paper presented at the Second Annual Congress for Recombinant DNA Research, Los Angeles, February 1982.
19. Belle-Isle, H., Herrick, S. K., Hartman, C. P. and Rabussay, D. End-labeling of DNA fragments with *E. coli* DNA Polymerase I. *Federation Proceedings* 41:1197, 1982.
20. Rabussay, D. Electroporation of mammalian and plant cells. *Abstract* of a tutorial presented at the 72nd Annual Meeting of FASEB, Las Vegas, Nevada, May 1998.
21. Jessee, J., Uher, L., Bloom, F. and Rabussay, D. Electroporation of *Escherichia coli* and other Microorganisms. *Abstract* of a poster presented at the FASEB meeting, San Francisco, California, January 1989.
22. Rabussay, D. Transdermal and transmembrane drug delivery by electroporation. *Invited lecture* at the Third International SRI Conference on Drug Delivery Technologies, Princeton, NJ, July 1998.
23. Dev, S. B. and Rabussay, D. Electroporation therapy marches on. *Cancer Watch* 7:123-124, 1998.
24. Rabussay, D. Electrically assisted drug delivery methods--opportunities and obstacles for therapeutic applications. *Synopsis* of an invited lecture delivered at a Conference on Drug Delivery Systems (Organizer: The Center for Business Intelligence), San Diego, California, January 1999.
25. Rabussay, D. Electroporation: A novel method for preventing restenosis and stimulating angiogenesis. *Synopsis* of an invited lecture delivered at a conference for Medical Device Executives on Cardiovascular Medicine (Organizer: American Health Consultants *et al.*), New Orleans, Louisiana, March 1999.
26. Widera, G., N. B. Dev, Nolan, E., Hofmann, G. A., and Rabussay, D. Immune responses after DNA vaccination augmented by *in vivo* electroporation. *Abstract* of a paper presented at the Keystone Symposium on DNA Vaccines: Immune Responses, Mechanisms, and Manipulating Antigen Processing, Snowbird, Utah, April 1999.

27. Widera, G., Dev, N. B., Nolan, E., Hofmann, G. A. and Rabussay, D. Increased Immune Response to DNA vaccines upon intracellular delivery by electroporation. *Synopsis* of an invited paper presented at the International Conference on Gene Therapy and Molecular Biology & Medicine, Redwood City, California, April 1999.
28. Nolan, E., Widera, G., Austin, M., Blecher, S. and Rabussay, D. High-level transgene expression and immune response after electroporation-enhanced gene delivery into rodent skeletal muscle. *Abstract* of a paper presented at the 2nd Annual Meeting of the American Society of Gene Therapy, Washington, D.C., June 1999.
29. Nanda, G. S., Dev, S. B., Blecher, S., Hofmann, G. A., and Rabussay, D. A novel treatment modality for head and neck tumors. *Abstract* of a poster presented at the 8th International Conference on Differentiation Therapy, Montreal, Canada, October 1999.
30. Dev, S., Nolan, E., Dev, N. B., Rabussay, D., Widera, G. and Nishi, T. Delivering genes by in vivo electroporation for therapeutic use. *Abstract* presented at the 4th Gene Delivery and Cellular Protein Expression Conference, Lake Tahoe, California, October 17-21, 1999.
31. Dev, N. B., Dev, S. B., Hofmann, G. A. and Rabussay, D. Pulsed electric field (electroporation) mediated inhibition of neointima in rat carotid artery. *Abstract* of a paper presented at the 51st Annual Conference of the Cardiology Society of India, New Delhi, India, December 1999.
32. Widera, G., Nolan, E., Zhang, L. and Rabussay, D. *In vivo* electroporation: A method to augment DNA delivery for gene therapy and DNA vaccination applications in muscle and skin. *Abstract*, Keystone Symposia, Gene Therapy, Keystone, Colorado, January 1-12, 2000.
33. Zhang, L., Widera, G., Nolan, E., Austin, M., Blecher, S., Primavera, J. and Rabussay, D. P. Highly efficient delivery of naked DNA into skin by non-invasive in vivo electroporation for gene therapy and DNA vaccination applications. *Abstract*, 1st International Conference of Cutaneous Gene Therapy: Problems and Prospects, NIH, Bethesda, Maryland, March 23-24, 2000.
34. Nolan, E., Zhang, L., Blecher, S., Primavera, J., and Rabussay, D. P. Electroporation enhanced delivery of the erythropoietin gene to rat skin. *Abstract*, First International Conference of Cutaneous Gene Therapy: Problems and Prospects, NIH, Bethesda, Maryland, March 23-24, 2000.
35. Nanda, G. S., Blecher, S. D., Austin, M. B., Hofmann, G. A., Rabussay, D. P. and Dev, S. B. Electroporation enhances the therapeutic efficacy of anticancer drugs. *Abstract* (& poster), AACR, San Francisco, California, April 3, 2000.
36. Zhang, L., Nolan, E., Widera, G., Austin, M., Blecher, S., Primavera, J., and Rabussay, D. P. Non-invasive *in vivo* electroporation: Efficient DNA delivery for gene therapy in skin. *Abstract*, Millennial World Congress of Pharmaceutical Sciences, San Francisco, California, April 11-20, 2000.
37. Widera, G., Austin, M., Rabussay, D., Goldbeck, C., Barnett, S., Chen, M., Leung, L., Otten, G. R., Thudium, K., Selby, M. J. and Ulmer, J. B. *In vivo* electroporation: A method to increase DNA vaccine delivery and immunogenicity. *Abstract*, 3rd Annual Meeting of the American Society of Gene Therapy, Denver, Colorado, May 31-June 4, 2000.

38. Nolan, E. M., Zhang, L., Bleecher, S., Primavera, J., Mehta, V., Nordstrom, J. L., Smith, L. C. and Rabussay, D. P. Electroporation enhanced delivery of the erythropoietin gene to rat skin. *Abstract*, 3rd Annual Meeting of the American Society of Gene Therapy, Denver, Colorado, May 31-June 4, 2000.
39. Zhang, L., Widera, G., Nolan, E., Austin, M., Bleecher, S., Primavera, J., and Rabussay, D. P. Effective non-viral approach for cutaneous gene therapy: Enhanced naked DNA transfer in *in vivo* electroporation. *Abstract*, 3rd Annual Meeting of the American Society of Gene Therapy, Denver, Colorado, May 31-June 4, 2000.
40. Dev, N. B., Primavera, J., Bleecher, S., Widera, G. and Rabussay, D. A strong enhancement of *in vivo* gene transfer into the ischemic skeletal muscle in the rat by pulsed electric fields. *Abstract*, 3rd Intl. Congress on Coronary Artery Disease, Lyon, France, October 2000.
41. Zhang, L., Azadzi, K., Chang, S. L., Banga, A. K., Hofmann, G. A., Rabussay, D. P. and Goldstein, I. Potential non-invasive approach to ameliorate male erectile dysfunction by electroporation: A feasibility evaluation *in vitro*, in rabbit, and in human subjects. *Abstract* P8 presented November 2000 at the 12th Symposium on Corpus Cavernosum Revascularization, International Journal of Impotence Research 13 (S1) S17, Northern Australia, April, 2001.
42. Dev, S. B., Rabussay, D., Bharathi, A., Siddiqi, J., and Hamid, Q. The bcl-2 family of genes is substantially regulated in cancer cells with the anticancer drug bleomycin only when combined with pulsed electric fields. *Abstract*, 2001 Keystone Symposia, Keystone, Colorado, January 16-22, 2001.
43. Dev, N. B., Widera, G., Primavera, J., Bleecher, S. and Rabussay, D. P. Strong enhancement of *in vivo* gene transfer into rat ischemic skeletal muscle by pulsed electric fields. *Abstract*, American College of Cardiology, Orlando, Florida, March 17-22, 2001.
44. Dev, S. B., Nanda, G. S., Bleecher, S., Rabussay, D. P., Moerland, T. S., Caban, J. B., Gibbs, S. J., and Locke, B. R. Magnetic resonance studies of laryngeal tumors implanted in nude mice: Effect of treatment with bleomycin and electroporation. *Abstract*, AACR, New Orleans, Louisiana, March 24-28, 2001.
45. Nanda, G. S., Bleecher, S. D., Rabussay, D. P. and Dev, S. B. Increased efficacy of anticancer drugs with electroporation therapy in the treatment of HEP-2 tumors. *Abstract*, AACR, New Orleans, Louisiana, March 24-28, 2001.
46. Nanda, G. S., Bleecher, S., Dev, S. B., and Rabussay, D. Electroporation therapy of head and neck tumors. *Abstract*, 7th International Congress on Oral Oncology, The Hague, The Netherlands, April 22-26, 2001.
47. Nanda, G. S. and Rabussay, D. Safety of head and neck tumor treatment by electroporation therapy. *Abstract*, 7th International Congress on Oral Oncology, The Hague, The Netherlands, April 22-26, 2001.
48. Nanda, G. S. and Rabussay, D. P. Effect of electroporation and electrochemotherapy on healthy tissue. *Abstract*, XVIth Symposium on Bioelectrochemistry and Bioenergetics (BEB 2001), Bratislava, Slovak Republic, June 1-6, 2001.

49. Zhang, L. and Rabussay, D. P. Clinical evaluations of safety and human tolerance of electrical sensation induced by non-invasive skin electroporation. *Abstract*, XVIth Symposium on Bioelectrochemistry and Bioenergetics (BEB 2001), Bratislava, Slovak Republic, June 1-6, 2001.
50. Rabussay, D. P. Advances in electroporation therapy. *Abstract* of an invited lecture, ElectroMed 2001, Second International Symposium on Nonthermal Medical/Biological Treatments Using Electromagnetic Fields and Ionized Gases, Portsmouth, Virginia, May 20-23, 2001.
51. Rabussay, D. P. Enhancing the effectiveness of gene and drug-based cancer therapy by electroporation. *Abstract*, International Conference on Technology in Cancer Research and Treatment in the New Millennium, Albany, New York, June 27-30, 2001.
52. Rabussay, D. P. Enhancement of drug and DNA delivery to healthy and malignant cells by electroporation. *Abstract* of an invited lecture, Inaugural Conference, Electromagnetic Methods in Pharmacy and Medicine, Darwin College, University of Kent at Canterbury, U.K., April 8-10, 2002.
53. Widera, G., Rabussay, D., Babiuk, S., Baca-Estrada, M. E., Foldvari, M. and Babiuk, L. A. *In vivo* electroporation: A method to improve the efficacy of intramuscular DNA vaccination in large animals. *Abstract* of a poster presentation, Keystone Symposium on Gene-Based Vaccines: Mechanisms, Delivery Systems and Efficacy (D3), Breckenridge, Colorado, April 10-15, 2002.
54. Babiuk, S., Baca-Estrada, M. E., Foldvari, M., Baizer, L., Stout, R., Rabussay, D., Widera, G. and Babiuk, L. A. Improving the efficacy of intradermal DNA vaccination by non-invasive electroporation in large animals. *Abstract* of a poster presentation, Keystone Symposium on Gene-Based Vaccines: Mechanisms, Delivery Systems and Efficacy (D3), Breckenridge, Colorado, April 10-15, 2002.
55. Dev, N. B., Joseph, M., Rabussay, D. P. Efficient *in vivo* transgene expression in the vascular wall driven by endovascular electroporation. *Abstract* of a poster presentation, 5th Annual Meeting of the American Society of Gene Therapy, Boston, Massachusetts, June 5-9, 2002.
56. Zhang, L., Widera, G., Holt, D., Bloom, D., Lindsay, F., Cupp, C. L. and Rabussay, D. P. Improving electroporation-enhanced *in vivo* gene delivery to skeletal muscle. *Abstract* of a poster presentation, 5th Annual Meeting of the American Society of Gene Therapy, Boston, Massachusetts, June 5-9, 2002.
57. Rabussay, D. P. Medical applications of electroporation of cell membranes. *Abstract* of an invited lecture, Workshop on Dielectric Properties and Electrical Breakdown of Biological Membranes, Cancun, Mexico, October 20, 2002.
58. Fewell, J. G., Wilson, E., Rabussay, D., and Nordstrom, J. L. Regulated erythropoietin expression following intramuscular plasmid administration in rats: Optimization of electroporation conditions. *Abstract* at 10th annual meeting of the European Society of Gene Therapy, Antibes Juan-les-Pins, France, October 12-16, 2002.

Theses

1. "Redoxbestimmungen mit 110m Silber-Metal" (Redox analyses using metallic 110 Silver), Master's thesis, ("Diplomarbeit") Technical University, Graz, Austria.
2. "Zur Expression der genetischen Information" (On the expression of genetic information), Doctoral thesis, Max Planck Institute for Biochemistry, Munich, West Germany.

Patents

1. Rabussay D.
Method of dental treatment.
United States Patent No. 4,355,022 (October 19, 1982).
2. Hofmann, G. A. and Rabussay, D.
Flow-through electroporation system for ex vivo gene therapy.
United States Patent No. 6,027,488 (February 22, 2000).
3. Hofmann, G. A., Rabussay, D. and Tonnessen, A.
Apparatus and method for the delivery of drugs and genes into tissue.
United States Patent No. 6,192, 270B1 (February 20, 2001).
4. Zhang, L., Hofmann, G. A., Rabussay, D.
Electrically assisted transdermal method and apparatus for the treatment of erectile dysfunction.
United States Patent No. 6,266,560 (July 24, 2001).
5. Hofmann, G. A., Rabussay, D. and Zhang, L.
Method of electroporation-enhanced delivery of active agents.
Allowed September 6, 2002